Infliximab treatment of rheumatoid arthritis
- 1 May 2004
- journal article
- review article
- Published by Elsevier in Rheumatic Disease Clinics of North America
- Vol. 30 (2) , 329-347
- https://doi.org/10.1016/j.rdc.2004.01.009
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseasesNature Medicine, 2003
- Foreword: It's a grand year for celebrating scienceNature Medicine, 2003
- Anti-TNFα Therapy of Rheumatoid Arthritis: What Have We Learned?Annual Review of Immunology, 2001
- Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α: Findings in open-label and randomized placebo-controlled trialsArthritis & Rheumatism, 2000
- ROLE OF CYTOKINES IN RHEUMATOID ARTHRITISAnnual Review of Immunology, 1996
- Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritisThe Lancet, 1994
- Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritisThe Lancet, 1994
- Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor αArthritis & Rheumatism, 1993
- Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis.Proceedings of the National Academy of Sciences, 1992
- Tumour necrosis factor-α in murine autoimmune 'lupus' nephritisNature, 1988